Evidence map›Paper›PMID 36299463›Full record

ArticleFrontiers in endocrinology2022

Proteomics analysis of cancer tissues identifies IGF2R as a potential therapeutic target in laryngeal carcinoma.

Bing Liu, Yuqiang Hu, Lixia Wan, Luan Wang, Liangjun Cheng, Hai Sun, Yaran Liu, Di Wu, Jiefei Zhu, Xiu Hong and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Chaperonin in health and disease.Molecular biomedicine · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Bing LiuXuzhou Clinical School, Xuzhou Medical University, Xuzhou, China.
Yuqiang HuXuzhou Clinical School, Xuzhou Medical University, Xuzhou, China.
Lixia WanDepartment of Psychology, Xuzhou Central Hospital, Xuzhou, China.
Luan WangXuzhou Clinical School, Xuzhou Medical University, Xuzhou, China.
Liangjun ChengXuzhou Clinical School, Xuzhou Medical University, Xuzhou, China.
Hai SunXuzhou Clinical School, Xuzhou Medical University, Xuzhou, China.
Yaran LiuInstitute of Medical Artificial Intelligence, Binzhou Medical College, Yantai, China.
Di WuDepartment of Pathology, Xuzhou Central Hospital, Xuzhou, China.
Jiefei ZhuDepartment of Pathology, Xuzhou Central Hospital, Xuzhou, China.
Xiu HongCentral laboratory, Xuzhou Central Hospital, Xuzhou, China.
Yang LiCentral laboratory, Xuzhou Central Hospital, Xuzhou, China.
Chong ZhouXuzhou Clinical School, Xuzhou Medical University, Xuzhou, China.
Xuzhou Central Hospital · CNBinzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Laryngeal cancer (LC) is a prevalent head and neck malignancy; however, the essential pathophysiological mechanism underlying its tumorigenesis and progression remains elusive. Due to the perduring scarcity of effective targeted drugs for laryngeal cancer, insights into the disease's pathophysiological mechanisms would substantially impact the treatment landscape of laryngeal cancer. Methods: To ensure quality consistency, 10 tumor and 9 non-tumor samples underwent proteomic analysis on a single mass spectrometer using a label-free technique. Subsequently, gene expression variations between laryngeal squamous cell carcinoma and normal tissues were analyzed using The Cancer Genome Atlas (TCGA) database. Immunohistochemical expressions of insulin-like growth factor 2 receptor (IGF2R), fibronectin (FN), vimentin, and α-smooth muscle actin (SMA) in LC tissues and normal tissues were determined. Results: In the tumor group, significant variations were detected for 433 upregulated and 61 downregulated proteins. Moreover, the heatmap revealed that the expressions of RNA translation-related proteins and proteins involved in RNA metabolism, such as IGF2R, tenascin C (TNC), periostin (POSTN), proteasome 26S subunit ATPase 4 (PSMC4), serpin family A member 3 (SERPINA3), heat shock protein family B (small) member 6 (HSPB6), osteoglycin (OGN), chaperonin containing TCP1 subunit 6A (CCT6A), and chaperonin containing TCP1 subunit 6B (CCT6B), were prominently elevated in the tumor group. Nonsense-mediated RNA decay (NMD), RNA translation, and protein stability were significantly altered in LC tumors. IGF2R was remarkably upregulated in LC tumors. In the TCGA database, the IGF2R mRNA level was significantly upregulated in LSCC tissues. Additionally, IGF2R mRNA expression was lowest in clinical grade 1 samples, with no significant difference between grades 2 and 3. In LSCC patients, a significant positive correlation between IGF2R expression and the stromal score was detected using the ESTIMATE algorithm to estimate the immune score, stromal score, and tumor purity in the tumor microenvironment. Lastly, immunohistochemical analysis revealed that IGF2R is overexpressed in LC. Conclusion: These results demonstrate the vital role of IGF2R in LC carcinogenesis and progression and may facilitate the identification of new therapeutic targets for the prevention and treatment of LC.

Indexed as

Carcinoma, Squamous CellLaryngeal NeoplasmsActinsAdenosine TriphosphatasesChaperonin Containing TCP-1ChaperoninsFibronectinsHeat-Shock ProteinsHumansProteasome Endopeptidase ComplexProteomicsReceptor, IGF Type 2RNA, MessengerSerpinsSomatomedinsTenascinActinsAdenosine TriphosphatasesCCT6A protein, humanChaperonin Containing TCP-1ChaperoninsFibronectinsHeat-Shock ProteinsIGF2R protein, humanProteasome Endopeptidase ComplexReceptor, IGF Type 2RNA, MessengerSerpinsSomatomedinsTenascinVimentinIGF2R (receptor of insulin growth factor 2)laryngeal cancerproteomicstarget therapeuticTCGA

Identifiers

PMID36299463
PMCPMC9592118
OpenAlexW4303968562

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.